Paper2863676
Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.
Auerbach HS and 3 others. Lancet, 1985. Cited by 279 papers, by iCite.
Cite this record
ConductScience Library. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Papers, record 2863676. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2863676
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystic Fibrosis | Major topic |
| Prednisone | Major topic |
| Respiration | Major topic |
| Body Height | |
| Body Weight | |
| Child | |
| Child, Preschool | |
| Clinical Trials as Topic | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Humans | |
| Immunoglobulin G | |
| Infant | |
| Pulmonary Ventilation | |
| Random Allocation | |
| Vital Capacity |
Source PubMed
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 279 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38096105 | Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis. | Ann Am Thorac Soc | 2024 | https://conductscience.org/library/papers/38096105 | PubMed |
| 36149378 | Appetite stimulants for people with cystic fibrosis. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/36149378 | PubMed |
| 33935699 | Cystic Fibrosis Lung Disease in the Aging Population. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33935699 | PubMed |
| 32848733 | Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32848733 | PubMed |
| 32288449 | Infections in cystic fibrosis. | Semin Pediatr Infect Dis | 1995 | https://conductscience.org/library/papers/32288449 | PubMed |
| 31813753 | Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function. | J Cyst Fibros | 2020 | https://conductscience.org/library/papers/31813753 | PubMed |
| 29922157 | Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/29922157 | PubMed |
| 28656134 | Corticosteroid-resistant inflammatory signalling in Pseudomonas-infected bronchial cells. | ERJ Open Res | 2017 | https://conductscience.org/library/papers/28656134 | PubMed |
| 28559270 | Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28559270 | PubMed |
| 27347364 | Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. | Ther Adv Chronic Dis | 2016 | https://conductscience.org/library/papers/27347364 | PubMed |
| 27189798 | Cystic fibrosis. | Nat Rev Dis Primers | 2015 | https://conductscience.org/library/papers/27189798 | PubMed |
| 26747453 | Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms. | Drugs R D | 2016 | https://conductscience.org/library/papers/26747453 | PubMed |
| 26649765 | Oral steroids for long-term use in cystic fibrosis. | Cochrane Database Syst Rev | 2015 | https://conductscience.org/library/papers/26649765 | PubMed |
| 23880054 | Antibiotic and anti-inflammatory therapies for cystic fibrosis. | Cold Spring Harb Perspect Med | 2013 | https://conductscience.org/library/papers/23880054 | PubMed |
| 22481418 | Cystic fibrosis: a mucosal immunodeficiency syndrome. | Nat Med | 2012 | https://conductscience.org/library/papers/22481418 | PubMed |
| 22105373 | Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. | Eur J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22105373 | PubMed |
| 22096358 | Potential of anti-inflammatory treatment for cystic fibrosis lung disease. | J Inflamm Res | 2010 | https://conductscience.org/library/papers/22096358 | PubMed |
| 21500868 | Targeting airway inflammation in cystic fibrosis in children: past, present, and future. | Paediatr Drugs | 2011 | https://conductscience.org/library/papers/21500868 | PubMed |
| 21454676 | Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21454676 | PubMed |
| 21233507 | Clinical significance of microbial infection and adaptation in cystic fibrosis. | Clin Microbiol Rev | 2011 | https://conductscience.org/library/papers/21233507 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2863676
GET https://conductscience.org/api/papers/v1/2863676/cited_by?page=2